source
- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.Fierce Biotech · 7d ago↗ source
- STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptidesThe panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.STAT · 8d ago↗ source
- Update: FDA does not freeze CRL trove as ‘radical transparency’ push hits speedbumpAn unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy “contravenes decades of agency practice.”